Open Your FREE Demat Account Now!

N/A
indicator

Nifty Healthcare Index

1D
1M
3M
6M
1Y
5Y
empty graph

Nifty Healthcare Index Performance

Low

₹15,894.90

High

₹16,104.00

52 Week Range

Low

₹13,536.50

High

₹16,941.70

Previous Close ₹16,095.55
Day's Range ₹15,894.90 - ₹16,104.00
Open ₹16,028.65
52 Week Range ₹13,536.50 - ₹16,941.70
Volume 1,41,89,703

Nifty Healthcare Index Companies

Company Name LTP (₹) Change (₹) Sector
Cipla Ltd. 1333.90 Arrow -10.10 (-0.75%) Healthcare
Dr. Reddy's Laboratories Ltd. 1196.40 Arrow -9.80 (-0.81%) Healthcare
Lupin Ltd. 2010.10 Arrow -21.10 (-1.04%) Healthcare
Torrent Pharmaceuticals Ltd. 4742.10 Arrow -25.20 (-0.53%) Healthcare
Abbott India Ltd. 26225.00 Arrow -615.00 (-2.29%) Healthcare
Apollo Hospitals Enterprise Ltd. 8042.00 Arrow -91.50 (-1.12%) Healthcare
Ipca Laboratories Ltd. 1964.50 Arrow 21.30 (1.10%) Healthcare
Sun Pharmaceutical Industries Ltd. 1784.30 Arrow -16.70 (-0.93%) Healthcare
Aurobindo Pharma Ltd. 1673.00 Arrow -3.80 (-0.23%) Healthcare
Glenmark Pharmaceuticals Ltd. 2280.60 Arrow -50.40 (-2.16%) Healthcare

All Indices

Index Name Market Value 52W High 52W Low
Nifty 50 22474.25 26373.20 22182.55
Nifty IT 28272.85 40301.40 25699.10
Nifty Next 50 68948.55 75000.40 59896.10
NIFTY50 USD Index 8085.85 10443.40 7994.05
Nifty Bank 54613.6 61764.85 49954.85
NIFTY Midcap 100 58970.65 64450.90 52032.85
Nifty 500 21898.6 24144.20 20385.65
Nifty Midcap 50 16874.9 18500.95 14804.55
Nifty 100 23558.95 26975.15 22720.45
Nifty FMCG 43964.75 57445.20 43442.30

Latest News

Oct
3
2026
EQUITY Posted on Oct 3rd 2026

Aurobindo Pharma informs about acquisition

Aurobindo Pharma has informed that this is with refer to letters dated July 23, 2026, September 12, 2026 and October 01, 2026, informing that Apitoria Pharma Private Limited (Apitoria), a wholly owned subsidiary of the Company, is acquiring the Contract Research Services business of A1 Biochem Group. A1 Biochem USA Inc (A1 USA Inc), which is a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited (A1 Labs India), has acquired 100% ownership of A1 Biochem Labs LLC (A1 Labs LLC) in accordance with the terms of the Definitive Agreements entered into for the acquisition of A1 Biochem Group. A1 Labs LLC is operating from USA and will now be a step-down subsidiary of A1 Labs India. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
3
2026
EQUITY Posted on Oct 3rd 2026

Abbott India informs about newspaper advertisement

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, and in compliance with the Circular issued by Securities and Exchange Board of India dated January 30, 2026, Abbott India has informed that it enclosed the newspaper advertisement, pertaining to the opening of special window for transfer and dematerialization of physical securities, published in the Business Standard (All Editions) and Loksatta today, Friday, October 2, 2026.

The above information is a part of company’s filings submitted to BSE.

Read More
Oct
1
2026
EQUITY Posted on Oct 1st 2026

Gland Pharma informs about disclosure

Gland Pharma has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial. 
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
29
2026
EQUITY Posted on Sep 29th 2026

Gland Pharma informs about newspaper publication

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Gland Pharma has enclosed copies of the newspaper publication titled ‘Notice for attention of members of Gland Pharma Limited’ published in the English and Telugu newspapers.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
28
2026
EQUITY Posted on Sep 28th 2026

Lupin informs about press release

Lupin has informed that it enclosed a Press Release titled ‘Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension’.
The above information is a part of company’s filings submitted to BSE. 
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Frequently Asked Questions

What is the Previous Close of NIFTYHEALTH index?

The previous close of NIFTYHEALTH index is ₹15926.05 as of 2026-10-05.

The total volume of NIFTYHEALTH index is 14189703.00 as of 2026-10-05.

The percentage change in value of NIFTYHEALTH index is -1.05% as of 2026-10-05.

The absolute increase in NIFTYHEALTH index value since the previous trading day is ₹-169.5 as of 2026-10-05.

A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.

View More
Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore